Crowther MA, Ann Intern Med 127: 333, 1997
Protocols to Start Warfarin Therapy: FENNERTY
10mg Loading Dose : for patients with no Risk Factors comorbidities or potentiating medicines
Starting Warfarin |
||
Day |
INR* |
Warfarin dose (mg) |
1. |
<1.4 |
10 |
2. |
< 1.8 |
10 |
|
1.8 |
1 |
|
> 1.8 |
0.5 |
3. |
< 2.0 |
10 |
|
2.0 – 2.1 |
5 |
|
2.2 – 2.3 |
4.5 |
|
2.4 – 2.5 |
4 |
|
2.6 – 2.7 |
3.5 |
|
2.8 – 2.9 |
3 |
|
3.0 – 3.1 |
2.5 |
|
3.2 – 3.3 |
2 |
|
3.4 |
1.5 |
|
3.5 |
1 |
|
3.6 – 4.0 |
0.5 |
|
> 4.0 |
0 |
4. |
<1.4 |
> 8 |
|
1.4 |
8 |
|
1.5 |
7.5 |
|
1.6 – 1.7 |
7 |
|
1.8 |
6.5 |
|
1.9 |
6 |
|
2.0 – 2.1 |
5.5 |
|
2.2 – 2.3 |
5 |
|
2.4 – 2.6 |
4.5 |
|
2.7 – 3.0 |
4 |
|
3.1 – 3.5 |
3.5 |
|
3.6 – 4.0 |
3 |
|
4.1 – 4.5 |
Miss out next day’s dose then give 2mg |
|
> 4.5 |
Miss out 2 days doses then give 1 mg |
INR - International Normalized Ratio APTT - activated partial thromboplastin time *APTT should be within or below therapeutic range (1.5 – 2.5 x control). If APTT is above this range, the heparin effect on INR should be neutralised by adding protamine (0.4 mg / ml plasma) to the sample. Reference: Drug and Therapeutics Bulletin 1992; 30: 77 – 80 Fennerty A et al, Anticoagulants in venous thromboembolism. BMJ 1988; 297: 1285 - 8 |